Air Liquide completes the divestiture of schülke

Paris, France, August 3, 2020

In accordance with its announcement on April 7, 2020, Air Liquide has closed the sale of its subsidiary schülke to EQT, a global investment organization. The total value of the transaction, which is subject to an earn-out provision, is between 925 million euros and 1.0 billion euros.

This transaction illustrates Air Liquide’s strategy to review its business portfolio regularly and to focus on its core gases and healthcare businesses, thereby enhancing Air Liquide’s performance.

Air Liquide intends to continue to develop its healthcare activities, while providing Schülke & Mayr GmbH with the best opportunity for its long-term development.

Schülke & Mayr GmbH, headquartered in Germany, is a leader in infection prevention and hygiene for more than 130 years. schülke develops, produces and distributes antiseptics for wound care, disinfectants, medical and cosmetic skin care products and preservatives. The company offers its customers innovative products, technologies and services in its core business fields:  Healthcare, Industrial Hygiene and Personal Care. Schülke’s mission is to protect lives worldwide and therewith actively contributes to patient safety. Today, the company employs over 1,250 employees worldwide and sells its products in over 100 countries. Represented by 22 subsidiaries, schülke operates three production sites in Germany (schülke), France (Bioxal) and Brazil (Vic Pharma).

www.schuelke.com

EQT is a differentiated global investment organization with more than EUR 62 billion in raised capital and around EUR 40 billion in assets under management across 19 active funds. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 27 billion and approximately 159,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.

top_page